Formulary

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

Retrieved on: 
Thursday, January 18, 2024
Knowledge sharing, Formulary, Economics, Food, FDA, Pain

EMERYVILLE, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) --  XOMA Corporation (NASDAQ: XOMA) announced today it has acquired an economic interest in DSUVIA® (sufentanil sublingual tablet) from Talphera, Inc., for $8 million.   DSUVIA® was approved in 2018 by the U.S. Food and Drug Administration (FDA) for use in adults in certified medically supervised healthcare settings.  In April 2023, Talphera divested DSUVIA® to Alora Pharmaceuticals for an upfront payment, a 15 percent royalty on commercial net sales, a 75 percent royalty on net sales to the U.S. Department of Defense (DoD), and up to $116.5 million in milestone payments.

Key Points: 
  • In April 2023, Talphera divested DSUVIA® to Alora Pharmaceuticals for an upfront payment, a 15 percent royalty on commercial net sales, a 75 percent royalty on net sales to the U.S. Department of Defense (DoD), and up to $116.5 million in milestone payments.
  • “The Talphera transaction is consistent with XOMA’s business model of acquiring royalty economics that we believe offer attractive and asymmetric risk/reward profiles.
  • We believe Alora has the resources and expertise to relaunch and successfully commercialize DSUVIA® within its expansive pain management portfolio,” stated Brad Sitko, Chief Investment Officer at XOMA.
  • Thereafter, XOMA fully retains the 15 percent royalty associated with DSUVIA® commercial sales, and the 75 percent royalties generated from DoD purchases will be shared equally between XOMA and Talphera, as will the remaining $116.5 million in potential milestone payments due from Alora Pharmaceuticals.

CWCI: California Workers’ Comp Independent Medical Reviews Increased in First Half of 2023

Retrieved on: 
Tuesday, August 1, 2023
Managed Care, Other Health, General Health, Professional Services, Pharmaceutical, Healthcare Reform, Hospitals, Health Insurance, Legal, Insurance, Human Resources, Health, Public Policy, Government, Injection, Medicine, Acupuncture, MTUS, Independent medical review, Formulary, IMR, Plasma protein binding, Manager, Pain management, Physician, Research, Letter, IMR-2, Pharmaceutical industry

CWCI’s review encompassed more than 1.3 million IMR decision letters issued from 2015 through June 2023 in response to applications submitted to the state after a Utilization Review (UR) physician modified or denied a workers’ comp medical service request.

Key Points: 
  • CWCI’s review encompassed more than 1.3 million IMR decision letters issued from 2015 through June 2023 in response to applications submitted to the state after a Utilization Review (UR) physician modified or denied a workers’ comp medical service request.
  • After climbing to a record 184,735 letters in 2018, IMR letter volume declined 31.1% over the next four years, falling to 127,215 letters in 2022.
  • IMR outcomes remained fairly stable, with IMR physicians upholding UR doctors’ modifications or denials 89.2% of the time in the first half of 2023 versus 91.1% of the time in 2022.
  • The 2023 uphold rates by type of service request ranged from 75.7% for evaluation/management services to 92.9% for acupuncture.

PartsSource Introduces Breakthrough Evidence-Based Model to Transform Service Contract Management for Healthcare Systems

Retrieved on: 
Thursday, June 15, 2023
Health Technology, Data Management, Technology, Finance, Radiology, Practice Management, Oncology, Professional Services, Medical Devices, Hospitals, Cardiology, Biotechnology, Software, Health, Medical Supplies, Medicine, AAMI, Workflow, HTM, Multimedia, Formulary, Hospital, Trade in Services Agreement, MD, Risk, Retail, Risk management, Health insurance

PartsSource ®, the leading online healthcare marketplace for mission-critical products and services, today announces PartsSource Repair and Service Agreements.

Key Points: 
  • PartsSource ®, the leading online healthcare marketplace for mission-critical products and services, today announces PartsSource Repair and Service Agreements.
  • View the full release here: https://www.businesswire.com/news/home/20230615665226/en/
    With digitally powered PartsSource Repair and Service Agreements, healthcare systems can now manage service events through a single standardized workflow featuring real-time updates, nationally benchmarked vendor performance monitoring and end-to-end event management, and powerful visual analytics.
  • PartsSource Repair and Service Agreements are transforming how health systems operate with five principles to resolve the issues uncovered by the study and bring better service to healthcare systems.
  • Formulary-driven standardized service management: PartsSource delivers end-to-end management of every service event with preferred vendor formulary rules.

CWCI Report Provides A Detailed Look at California WC Medical Dispute Resolution

Retrieved on: 
Friday, May 12, 2023
Health, Legal, Insurance, Human Resources, Healthcare Reform, Public Policy, Government, Pharmaceutical, Professional Services, Practice Management, General Health, Hospitals, Health Insurance, State, Local, Other Policy Issues, Injection, Medicine, Acupuncture, MTUS, Communication, PT, History, Formulary, Plasma protein binding, Manager, Pain management, Physician, Chronic pain, UR, Research, Roger Hawkins (drummer), Aladar Imre, IMR, Legislation, Pharmaceutical industry

IMR took effect for all claims in July 2013, and CWCI began tracking IMR activity in 2014.

Key Points: 
  • IMR took effect for all claims in July 2013, and CWCI began tracking IMR activity in 2014.
  • This can lead to a dispute, even though additional pills or PT visits can be requested later if the treatment proves successful.
  • In addition to providing new data on IMR volume and outcomes, the CWCI report reviews the history of dispute resolution in California workers’ compensation, details how medical dispute resolution in California workers’ compensation differs from other health care systems and notes the disproportionate share of disputed treatment requests that originate with a small percentage of high-volume providers – primarily pain management specialists and orthopedists.
  • CWCI has issued its analysis as a free Report to the Industry, “Resolving Medical Disputes: Factors that Drive IMR Volume and Outcomes in the California Workers’ Compensation System,” which is available here .

eNavvi and Mark Cuban Cost Plus Drug Company announce new collaboration to deliver prescription cost transparency

Retrieved on: 
Thursday, May 4, 2023
Insurance, DO, Cost Plus Drugs, Navigator, Physician, Formulary, Patient, Pharmacy, Health, PBC, Pharmaceutical industry

LOS ANGELES, May 4, 2023 /PRNewswire/ -- eNavvi, Inc., a leading provider prescription marketplace, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), an innovator in offering transparently priced medications, are thrilled to announce their new collaboration focused on delivering prescription cost transparency.

Key Points: 
  • LOS ANGELES, May 4, 2023 /PRNewswire/ -- eNavvi, Inc., a leading provider prescription marketplace, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), an innovator in offering transparently priced medications, are thrilled to announce their new collaboration focused on delivering prescription cost transparency.
  • This collaboration with Cost Plus Drugs will empower eNavvi's Marketplace to provide real-time cash-price transparency directly to physicians, ultimately making medications more affordable and accessible for patients.
  • "As a practicing physician I saw first-hand the danger of patients not taking their medications because they couldn't afford them," said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company.
  • "I founded the Mark Cuban Cost Plus Drug Company to help solve this problem and provide a way for patients to receive their medication at an affordable price.

NCPDP's Lee Ann Stember Awarded APhA Honorary Membership at APhA Annual Meeting

Retrieved on: 
Monday, March 27, 2023
Pharmacy, Public, White paper, Medication therapy management, COVID-19, Prescription, Formulary, MTM, Pharmacist, NCPDP, Documentation, Stember, Patient, Trustee, Patient safety, Paracetamol, American Pharmacists Association, Medicine, Health, Medication, Caregiver, Pharmaceutical industry, Health care, Nursing

SCOTTSDALE, Ariz., March 27, 2023 /PRNewswire-PRWeb/ -- NCPDP announced its President & CEO Lee Ann Stember was awarded APhA Honorary Membership at the APhA Annual Meeting & Exposition on Saturday, March 25. As the 2023 award recipient, Stember joins a distinguished list of individuals including scholars, scientists, government officials, dignitaries, and luminaries from across the world who have received the prestigious award since it was first presented in 1856. The award recipient is selected by the APhA Board of Trustees. Nominees must have documented activity that has significantly impacted public health or has created or supported the expanding role of pharmacists, the profession, or the Association.

Key Points: 
  • SCOTTSDALE, Ariz., March 27, 2023 /PRNewswire-PRWeb/ -- NCPDP announced its President & CEO Lee Ann Stember was awarded APhA Honorary Membership at the APhA Annual Meeting & Exposition on Saturday, March 25.
  • In accepting the award Stember thanked the APhA Board and those who nominated her for the award.
  • Stember stated, "We believe the frontline provider role that [pharmacists] played in the pandemic will forever change the profession.
  • Journalists: Click here to download a photo of Lee Ann Stember.

Curative Promotes Current Chief Financial Officer Tami Wilson-Ciranna to President

Retrieved on: 
Monday, March 13, 2023
Accounting, Professional Services, Insurance, Finance, Risk, University, MBA, Civil Service (United Kingdom), Formulary, Inc., CPA, Sale, University of California, Los Angeles, Human resources, Biotechnology, Investment management, Health, Multimedia, Telehealth, CalPERS, COVID-19 testing, Growth, PPO, Real estate, COVID-19, Health care, Management, Curative, Energy, Facility

Curative Inc., a leading health services company that recently launched a new health plan in the Austin area, has promoted Chief Financial Officer Tami Wilson-Ciranna, to President of the company, effective immediately.

Key Points: 
  • Curative Inc., a leading health services company that recently launched a new health plan in the Austin area, has promoted Chief Financial Officer Tami Wilson-Ciranna, to President of the company, effective immediately.
  • "Tami has been a crucial member of our C-Suite team since she joined Curative, and instrumental in the founding and launching of Curative Insurance Company,” said Fred Turner, CEO and co-founder of Curative.
  • She served as Chief Financial Officer for Curative Labs Inc. during the pandemic response that provided over 36 million tests around the United States, providing financial and operational expertise to help the nation manage its response efforts.
  • Wilson-Ciranna previously served as the Chief Financial and Administrative Officer at Prolacta Bioscience, a company that produces human milk-based nutritional products for premature infants.

Capital Rx Earns Surescripts® Certification & SOC 2 Type 2 Report

Retrieved on: 
Friday, February 10, 2023
Streamlining Claims Processing for Federal Contractor Employees Act, Surescripts, Security, Workflow, Prescription, Patient, Change management, Privacy, EHR, Partnership, AICPA, HTTPS, Tetraplegia, SOC, Cos, Formulary, TSC, Logical security, Payment, Cryptocurrency, Health insurance

Additionally, Capital Rx completed its SOC 2 Type 2 report for JUDI® , the industry's first cloud-native enterprise pharmacy platform, and its Claims Processing Services (as of June 30, 2022).

Key Points: 
  • Additionally, Capital Rx completed its SOC 2 Type 2 report for JUDI® , the industry's first cloud-native enterprise pharmacy platform, and its Claims Processing Services (as of June 30, 2022).
  • "Leveraging JUDI's open architecture, we can deliver the same 100% accurate information in the Capital Rx member app to prescribers."
  • The Surescripts certification received by Capital Rx is for Surescripts Real-Time Prescription Benefit and Connectivity direct to Surescripts via HTTPS.
  • Capital Rx has engaged with a third-party auditor to perform its SOC 1 Type 2, SOC 2 Type 2, and SOC 3 engagements in 2023 and beyond.

Jan. 15 ACA enrollment deadline fast approaching

Retrieved on: 
Friday, January 6, 2023
Legislation, Marriage, American Rescue Plan Act of 2021, ACA, Health policy, Formulary, Social Security, Family, Prescription, Insurance, Comparison, Hand, Affordable Care Act, Health insurance, Real estate, Life insurance

Today, healthinsurance.org offered tips to simplify the enrollment process and explained the risks of delaying — or skipping —  open enrollment.

Key Points: 
  • Today, healthinsurance.org offered tips to simplify the enrollment process and explained the risks of delaying — or skipping —  open enrollment.
  • “Missing the open enrollment deadline can be emotionally and financially damaging if it results in inadequate health insurance coverage,” said Louise Norris, health policy analyst for healthinsurance.org .
  • “It’s important to review your coverage options during open enrollment each year, even if you’re already insured and have been happy with your coverage,” Norris said.
  • There are resources available at no cost to consumers who have questions about the open enrollment process, or need help with their enrollment.

Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the RHO Phyto™ CBG Transdermal Gel Topical Product

Retrieved on: 
Wednesday, December 14, 2022
RHO, Fibromyalgia, Associate, Absorption, Science, Cannabis, Formulary, Toronto Stock Exchange, FSE, Dermatology, Terpene, Research, Rheumatoid arthritis, Nursing, Clinical trial, Inflammation, Chronic pain, McGill University, Wellness, Risk, CRS, TSX, R, Quality of life, CBG, News, Overalls, CBD, Social media, Patient, Data collection, Physician, Offering, Menthol, Cannabinoid, Eugenol, Muscle, Medical Affairs Bureau, SEDAR, Osteoarthritis, Arthritis, Medical device, Drug, Medicine, Pharmaceutical industry, Cannabigerol, Cannabidiol

The participants, as identified by the healthcare provider will take part in a 3-month study including clinical visits at baseline and 3-month follow-up assessment.

Key Points: 
  • The participants, as identified by the healthcare provider will take part in a 3-month study including clinical visits at baseline and 3-month follow-up assessment.
  • The study will be conducted by Santé Cannabis, an independent medical cannabis clinic and research services provider.
  • Santé Cannabis has developed a data collection platform and centred model in executing upon its role as a CRS and CRO.
  • The gel includes a combination of CBG and CBD in a fast-absorbing, water-based gel intended for application locally to area of focus.